Integrated thermal proteome and thermal proximity co-aggregation profiling identifies ATP6V1C1 as a novel anti-cancer drug target.

阅读:3
作者:Zhang Shuang, Li Feng-Ming, Wang Jun, Dong Yu, Luo Jing-Fang, Huang Xiao-Fang, Li Yue, Zhu Guo-Yuan, Qi Shi-Qian, Shen Han-Ming, Zhong Qing, Ming Chen, Zeng Ke-Wu, Yao Xiao-Jun, Tan Chris Soon Heng, Lu Jia-Hong
Bioactive natural products are invaluable sources for drug discovery. Unraveling their molecular targets uncovers the mechanisms of action and provides novel targets for drug development. However, the current approaches for target identification fall short in terms of efficiency, due to the extensive list of candidates and limited functional clues. Here we pioneer a strategy that integrates thermal proteome profiling and thermal proximity co-aggregation (TPP-TPCA) for high-efficient target identification. By linking functional targets to downstream perturbed protein complexes, this strategy enables a functional validation of candidate targets. For the first time, we applied this strategy to pinpoint the target of a natural compound veratramine (VAM) with anti-proliferation properties. Notably, the TPP identifies ATP6V1C1 as a candidate target of VAM, while TPCA reveals the dissociation of vacuolar (V)-ATPase. By directly binding to ATP6V1C1, VAM inhibits V-ATPase catalytic activity and lysosomal acidification, ultimately disrupting the autophagic-lysosomal pathway essential for cancer cell survival. Bioinformatics analysis reveals that ATP6V1C1 expression is upregulated in a variety of tumors and serves as a hub gene in breast cancer. Overall, this work presents an efficient strategy for target identification, demonstrating its successful application in identifying ATP6V1C1 as a promising target for cancer treatment.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。